glp-1 cv outcome trials Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular Diabetology Review of Cardiovascular Outcome Trials

Side effects comparison between medications A detailed semaglutide versus tirzepatide side effects comparison shows that while both medications share similar side effect profiles, the severity and duration can differ

Continuous GLP-1RA use for three years was associated with the greatest reduction in MACE risk compared with sulfonylureas, whereas interruptions and discontinuations were associated with a progressive attenuation of this protective effect, with risk estimates in some scenarios approaching those of the comparator group

You may need a dose adjustment rather than a timing change

However, patients enrolled in a Medicare Part D plan will be eligible for the Medicare GLP-1 Bridge program starting July 1